Necrotising Enterocolitis Market to Grow on Rising Preterm Births

Necrotising Enterocolitis Market to Grow on Rising Preterm Births

The necrotising enterocolitis (NEC) market encompasses a broad range of diagnostic, therapeutic, and supportive care products aimed at preventing and treating one of the most serious gastrointestinal emergencies in neonates. NEC primarily affects preterm and very low birth weight infants, often necessitating specialized interventions such as advanced parenteral nutrition solutions, immunoglobulin therapies, probiotics, and surgical devices. Probiotics and prebiotic supplements are being increasingly adopted due to their ability to foster a healthier gut microbiome, reduce the risk of severe inflammation, and improve overall neonatal outcomes. Parenteral nutrition products provide critical nutritional support for infants unable to feed enterally, while immunoglobulins offer passive immunity to reduce infection risks. Surgical staplers, anastomosis devices, and minimally invasive instruments have revolutionized NEC management by enabling precise resections and reducing postoperative complications.

The increasing number of premature births and the subsequently rising incidence of NEC is a major driver for Necrotising Enterocolitis Market growth. The convergence of technological advancements in neonatal intensive care units, rising survival rates of preterm infants, and growing clinician awareness have collectively driven demand for NEC-specific products. Robust pipeline developments, coupled with government initiatives to improve neonatal care standards in emerging regions, underscore the market’s attractiveness.

According to CoherentMI, The Global Necrotising Enterocolitis Market is estimated to be valued at USD 7.51 Billion in 2025 and is expected to reach USD 11.14 Billion by 2032, growing at a compound annual growth rate (CAGR) of 5.8% from 2025 to 2032.

Key Takeaways

Key players operating in the Necrotising Enterocolitis Market are

·         AbbVie

·         AstraZeneca

·         Baxter International

·         Bristol-Myers Squibb

·         Fresenius Kabi.

 These industry leaders have established robust portfolios spanning parenteral nutrition, neonatal immunotherapy, and surgical instruments tailored to NEC treatment. AbbVie’s research focus on biologics and gut health, AstraZeneca’s investment in neonatal infectious disease therapies, and Baxter International’s comprehensive line of total parenteral nutrition products underscore the competitive landscape. Bristol-Myers Squibb leverages strategic partnerships to accelerate development of immune-based treatments, while Fresenius Kabi capitalizes on its global manufacturing footprint to ensure product availability. Collectively, these players engage in mergers and acquisitions, research collaborations, and geographic expansions aimed at strengthening their NEC market positions and addressing unmet clinical needs.

The Necrotising Enterocolitis Market presents significant opportunities driven by advances in microbiome research, personalized neonatal care, and digital health integration. The growing body of evidence supporting probiotic efficacy in preventing NEC underpins new product launches and clinical trials. Personalized nutrition solutions, tailored immunoglobulin formulations, and point-of-care diagnostic tools offer avenues for differentiation. Expanding telemedicine and remote monitoring capabilities in neonatal intensive care units present untapped potential to optimize feeding protocols and early detection. Furthermore, increasing public–private partnerships and funding for neonatal research in emerging economies facilitate market penetration. Companies that harness data analytics, artificial intelligence, and real-world evidence to refine treatment algorithms and demonstrate health economic benefits are poised to capture these burgeoning opportunities.

Global expansion remains a central theme for Necrotising Enterocolitis Market players seeking to broaden their footprint and reach high-burden regions. North America dominates the market, buoyed by advanced healthcare infrastructure, high preterm birth survival rates, and strong reimbursement frameworks. Europe follows closely, propelled by strategic collaborations and well-established neonatal care networks. The Asia Pacific region is projected to witness the fastest growth, driven by rising healthcare expenditures, growing awareness of preterm care, and improving access to advanced therapies in China, India, and Southeast Asia. Latin America, the Middle East, and Africa are emerging as next-generation growth territories, with increasing government initiatives to reduce infant mortality and support neonatal intensive care development. Strategic alliances, localized manufacturing, and tailored pricing models will be pivotal for successful penetration in these diverse markets.

Market Drivers and Restraints:

Market Drivers

One of the foremost drivers propelling the Necrotising Enterocolitis Market is the increasing global incidence of preterm births coupled with significant advancements in neonatal intensive care. Improved survival rates of very low birth weight infants, due to cutting-edge incubators, respiratory support systems, and monitoring devices, have inadvertently led to a higher population at risk for NEC. As more preterm infants survive the neonatal period, the absolute number of NEC cases has risen, thereby stimulating demand for specialized therapies and diagnostic tools. Simultaneously, technological progress in minimally invasive surgical equipment, high-precision imaging modalities, and novel nutritional formulations has expanded treatment options. Heightened clinician awareness and standardized care protocols further drive early intervention strategies. Research investments targeting the neonatal gut microbiome and immune modulation are unveiling new prophylactic and therapeutic approaches, such as strain-specific probiotics and recombinant immunoglobulins. Governmental programs emphasizing maternal and neonatal health, especially in emerging economies, are allocating resources toward improving NICU capabilities. Collectively, these factors create a virtuous cycle: improved neonatal survival leads to greater NEC incidence, which in turn fuels market growth as stakeholders seek to mitigate this life-threatening condition.

Market Restraint

Despite significant growth prospects, the Necrotising Enterocolitis Market faces a major restraint in the form of high treatment costs and inconsistent reimbursement policies across regions. Advanced therapies—particularly biologics, recombinant immunoglobulins, and precision probiotics—often command premium pricing due to complex manufacturing processes and rigorous clinical validation requirements. Surgical interventions utilizing state-of-the-art minimally invasive tools also incur substantial capital and procedural expenses. In many emerging markets, limited healthcare budgets and lack of structured reimbursement frameworks hinder adoption of these high-cost solutions, restricting market penetration. Payers and hospital procurement departments remain cautious, often favoring established protocols over novel, expensive treatments. Variations in reimbursement codes and health insurance coverage across countries add further complexity, making it challenging for manufacturers to achieve predictable revenue streams. Additionally, the cost sensitivity of neonatal care centers in low- and middle-income regions results in reliance on basic supportive care rather than advanced intervention, thereby curtailing overall market expansion. Addressing these barriers requires concerted efforts to demonstrate robust health economic outcomes, engage policymakers for favorable reimbursement revisions, and develop cost-effective formulations without compromising clinical efficacy.

Segment Analysis

One primary way to segment the Necrotising Enterocolitis market is by treatment modality, which includes antibiotic therapy, probiotic supplementation, parenteral nutrition, and surgical intervention. Among these, antibiotic therapy represents the dominating sub-segment. This dominance stems from its early adoption in neonatal intensive care units, broad-spectrum efficacy against suspected bacterial pathogens, and well-established dosing protocols. Clinicians often administer antibiotics at the first sign of NEC to halt progression, making this sub-segment indispensable. Probiotic supplementation is a rapidly emerging sub-segment, driven by growing clinical evidence of its role in modulating gut microbiota and reducing NEC incidence. However, its adoption is tempered by regulatory variability and formulation standardization challenges. Parenteral nutrition serves as a vital supportive measure for infants unable to tolerate enteral feeds, but its application is more adjunctive than primary therapy, limiting overall revenue share. Surgical intervention, reserved for severe NEC cases with intestinal perforation or necrosis, commands significant per-case expenditures but represents a smaller patient population. As research intensifies around microbiome-based therapies and precision nutrition, probiotic formulations and novel biologics are poised to gain share. For now, antibiotic therapy holds the largest slice of the treatment modality segment due to clinical familiarity, guideline endorsement, and immediate impact on neonatal survival rates.

Global Analysis

The global NEC landscape reveals North America as the dominating region, supported by advanced neonatal care infrastructure, high adoption of evidence-based protocols, and substantial healthcare spending. The U.S. leads within this region thanks to widespread NICU availability, favorable reimbursement frameworks, and ongoing investment in neonatal research. Europe follows, bolstered by strong pediatric networks in countries like Germany and the U.K., though adoption rates vary across Eastern and Western Europe. Among emerging markets, Asia Pacific is the fastest-growing region.

Factors fueling its rapid expansion include rising birth rates, government initiatives to enhance neonatal care, and increasing investments in hospital modernization in countries such as China and India. Japan and South Korea also contribute, with well-established NICUs and growing clinical trial activity focusing on NEC prevention. Latin America and the Middle East & Africa show moderate growth, driven by incremental improvements in healthcare delivery and pilot programs aimed at reducing neonatal mortality. Nonetheless, infrastructure gaps and resource constraints temper growth in these areas. Overall, North America remains the largest revenue contributor, while Asia Pacific offers the most dynamic growth trajectory through 2032.

➢Get this Report in Japanese Language: 壊死性腸炎市場

➢Get this Report in Korean Language: 괴사성장염시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)